O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure

• Tipo: Artigo em Revista Científica Internacional
• Data: 2019

Autores

Kronlage, M (Autor) Outra; Dewenter, M (Autor) Outra; Grosso, J (Autor) Outra; Fleming, T (Autor) Outra; Oehl, U (Autor) Outra; Lehmann, LH (Autor) Outra; Falcao Pires, I (Autor) FMUP; Leite-Moreira AF (Autor) FMUP; Volk, N (Autor) Outra; Groene, HJ (Autor) Outra; Mueller, OJ (Autor) Outra; Sickmann, A (Autor) Outra; Katus, HA (Autor) Outra; Backs, J (Autor) Outra

Revista

Título: Circulation

Vol. 140

Páginas: 580-594

ISSN: 0009-7322

Editora: Wolters Kluwer Health

Indexação

ISI Web of Knowledge - 79 Citações

Scopus - 86 Citações

Outras Informações

ID Authenticus: P-00R-0CW

DOI: 10.1161/circulationaha.117.031942

Abstract (EN): Background: Worldwide, diabetes mellitus and heart failure represent frequent comorbidities with high socioeconomic impact and steadily growing incidence, calling for a better understanding of how diabetic metabolism promotes cardiac dysfunction. Paradoxically, some glucose-lowering drugs have been shown to worsen heart failure, raising the question of how glucose mediates protective versus detrimental cardiac signaling. Here, we identified a histone deacetylase 4 (HDAC4) subdomain as a molecular checkpoint of adaptive and maladaptive signaling in the diabetic heart. Methods: A conditional HDAC4 allele was used to delete HDAC4 specifically in cardiomyocytes (HDAC4-knockout). Mice were subjected to diabetes mellitus either by streptozotocin injections (type 1 diabetes mellitus model) or by crossing into mice carrying a leptin receptor mutation (db/db; type 2 diabetes mellitus model) and monitored for remodeling and cardiac function. Effects of glucose and the posttranslational modification by beta-linked N-acetylglucosamine (O-GlcNAc) on HDAC4 were investigated in vivo and in vitro by biochemical and cellular assays. Results: We show that the cardio-protective N-terminal proteolytic fragment of HDAC4 is enhanced in vivo in patients with diabetes mellitus and mouse models, as well as in vitro under high-glucose and high-O-GlcNAc conditions. HDAC4-knockout mice develop heart failure in models of type 1 and type 2 diabetes mellitus, whereas wild-type mice do not develop clear signs of heart failure, indicating that HDAC4 protects the diabetic heart. Reexpression of the N-terminal fragment of HDAC4 prevents HDAC4-dependent diabetic cardiomyopathy. Mechanistically, the posttranslational modification of HDAC4 at serine (Ser)-642 by O-GlcNAcylation is an essential step for production of the N-terminal fragment of HDAC4, which was attenuated by Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation at Ser-632. Preventing O-GlcNAcylation at Ser-642 not only entirely precluded production of the N-terminal fragment of HDAC4 but also promoted Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation at Ser-632, pointing to a mutual posttranslational modification cross talk of (cardio-detrimental) phosphorylation at Ser-632 and (cardio-protective) O-GlcNAcylation at Ser-642. Conclusions: In this study, we found that O-GlcNAcylation of HDAC4 at Ser-642 is cardio-protective in diabetes mellitus and counteracts pathological Ca2+/calmodulin-dependent protein kinase II signaling. We introduce a molecular model explaining how diabetic metabolism possesses important cardio-protective features besides its known detrimental effects. A deeper understanding of the here-described posttranslational modification cross talk may lay the groundwork for the development of specific therapeutic concepts to treat heart failure in the context of diabetes mellitus.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 15